BRPI0410714A - derivados de quinazolina - Google Patents

derivados de quinazolina

Info

Publication number
BRPI0410714A
BRPI0410714A BRPI0410714-4A BRPI0410714A BRPI0410714A BR PI0410714 A BRPI0410714 A BR PI0410714A BR PI0410714 A BRPI0410714 A BR PI0410714A BR PI0410714 A BRPI0410714 A BR PI0410714A
Authority
BR
Brazil
Prior art keywords
alkyl
independently represent
het
represent hydrogen
optionally substituted
Prior art date
Application number
BRPI0410714-4A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Timothy Pietro Suren Perera
Peter Jacobus Johan Buijnsters
Marc Willems
Gaston Stanislas Marcell Diels
Werner Constant Joha Embrechts
Peter Ten Holte
Carsten Schultz-Fademrecht
Frederik Jan Rita Rombouts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33493782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410714(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0410714A publication Critical patent/BRPI0410714A/pt
Publication of BRPI0410714B1 publication Critical patent/BRPI0410714B1/pt
Publication of BRPI0410714B8 publication Critical patent/BRPI0410714B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"DERIVADOS DE QUINAZOLINA". A presente invenção se refere a compostos da fórmula: as formas de N-óxido, os sais de adição farmaceuticamente aceitáveis e as formas estereoquimicamente isoméricas do mesmo, em que: Z representa NH; Y representa -C~ 3-9~ alquila-, -C~ 2-9~ alquenila-, -C~ 3-7~alquil-CO-NH opcionalmente substituída por amino, mono - ou di(C~ 1-4~alquil)amino ou C~ 1-4~ alquilóxicarbonilamino-, -C~ 3-7~alquenil-CO-NH- opcionalmente substituído por amino, mono- ou di(C~ 1~-4~alquil)amino- ou C~ 1-4~ alquilóxicarbonilamino-, C~ 1-5~alquil-NR~ 13~-C~ 1-5~ alquila-, C~ 1-5~alquil-NR¬ 14¬-CO-C~ 1-5~ alquila-, -C~ 1-6~alquil-CO-NH-, -C~ 1-5~alquil-CO NR¬ 15¬-C~ 1-5~ alquila-, -C~ 1-3~alquil-NH-CO-Het¬ 20¬-, -C~ 1-2~alquil-CO-Het¬ 21¬CO-, -C~ 1-2~alquil-NH-CO-CR¬ 16¬R¬ 17¬-NH-, -C~ 1-2~alquiL-CO-NH-CR¬ 18¬R¬ 19¬-CO-, -C~ 1-2~alquiL-CO-Nr¬ 20¬-C~ 1-3~alquil-CO- ou -NR¬ 22¬-CO-C~ 1-3~alquil-NH-; X¬ 1¬ representa uma ligação direta, O ou -O-C~ 1-2~ alquila-; X¬ 2¬ representa uma ligação direta, -CO-C~ 1-2~ alquila-, NR¬ 12¬,-NR¬ 12¬-C~ 1-2~ alquila-, -O-N=CH- ou -C~ 1-2~ alquila-; R¬ 1¬ e R¬ 2¬ representam, cada um independentemente, hidrogênio ou halo; R¬ 3¬ representa hidrogênio; R¬ 4¬ representa hidrogênio ou C~ 1-4~ alquilóxi; R¬ 12¬ e R¬ 13¬ representam, cada um independentemente, hidrogênio OU C~ 1-4~ alquila; R¬ 14¬ e R¬ 15¬ representa hidrogênio; R¬ 16¬ e R~ 17¬ representam, cada um independentemente, hidrogênio ou C~ 1-4~ alquila; R¬ 18¬ e R¬ 19¬ representam, cada um independentemente, hidrogênio ou C~ 1-4~ alquila opcionalmente substituída por fenila ou hidróxi; R¬ 20¬ e R¬ 21¬ representam, cada um independentemente, hidrogênio OU C~ 1-4~ alquila opcionalmente substituída por C~ 1-4~ alquilóxi; Het¬ 20¬, Het¬ 21¬ e Het¬ 22¬ representam, cada um independentemente, um heterociclo selecionado do grupo consistindo de pirrolidinila, 2-pirrolidinonila ou piperidinila opcionalmente substituída por hidróxi.
BRPI0410714A 2003-05-27 2004-05-25 derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso BRPI0410714B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP0305723 2003-05-27
EPPCT/EP03/05723 2003-05-27
EPPCT/EP03/10266 2003-09-15
EP0310266 2003-09-15
EP0351061 2003-12-18
EPPCT/EP03/51061 2003-12-18
PCT/EP2004/005621 WO2004105765A1 (en) 2003-05-27 2004-05-25 Macrocyclic quinazoline derivatives as antiproliferative agents

Publications (3)

Publication Number Publication Date
BRPI0410714A true BRPI0410714A (pt) 2006-06-13
BRPI0410714B1 BRPI0410714B1 (pt) 2019-09-24
BRPI0410714B8 BRPI0410714B8 (pt) 2021-05-25

Family

ID=33493782

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410714A BRPI0410714B8 (pt) 2003-05-27 2004-05-25 derivados de quinazolina macrocíclicos, seu processo de preparação, composição farmacêutica que os compreende e uso

Country Status (31)

Country Link
US (4) US7648975B2 (pt)
EP (2) EP2305687A1 (pt)
JP (1) JP4887151B2 (pt)
KR (1) KR101143878B1 (pt)
CN (1) CN102718775B (pt)
AR (2) AR045687A1 (pt)
AT (1) ATE544454T1 (pt)
AU (1) AU2004243487B2 (pt)
BR (1) BRPI0410714B8 (pt)
CA (1) CA2525214C (pt)
CL (1) CL2004001267A1 (pt)
CO (1) CO5640038A2 (pt)
CY (1) CY1113002T1 (pt)
DK (1) DK1633365T3 (pt)
EA (1) EA009064B1 (pt)
ES (1) ES2381976T3 (pt)
HR (1) HRP20120351T1 (pt)
IL (3) IL172154A0 (pt)
IS (1) IS3030B (pt)
JO (1) JO2785B1 (pt)
MX (1) MXPA05012762A (pt)
MY (1) MY148633A (pt)
NO (1) NO334209B1 (pt)
NZ (1) NZ544154A (pt)
PA (1) PA8603801A1 (pt)
PL (1) PL1633365T3 (pt)
PT (1) PT1633365E (pt)
SI (1) SI1633365T1 (pt)
TW (3) TWI379835B (pt)
UA (1) UA84010C2 (pt)
WO (1) WO2004105765A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
MXPA06007018A (es) * 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de 3-ciano-quinolino con actividad anti-proliferativa.
MXPA06007017A (es) 2003-12-18 2006-08-31 Janssen Pharmaceutica Nv Derivados de pirido y pirimidopirimidina como agentes antiproliferativos.
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
DK1854789T3 (da) 2005-02-23 2013-10-21 Shionogi & Co Quinazolinderivat med tyrosin-kinase inhibitorisk aktivitet
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
US8778919B2 (en) * 2005-06-30 2014-07-15 Janssen Pharmaceutica Nv Cyclic anilino—pyridinotriazines
JP2009542778A (ja) * 2006-07-13 2009-12-03 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｍｔｋｉキナゾリン誘導体
JP2009242240A (ja) * 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
EP2061469B8 (en) * 2006-09-11 2014-02-26 Curis, Inc. Quinazoline based egfr inhibitors
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2007296746B2 (en) 2006-09-11 2012-07-05 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
AU2007310842A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Use of a MT kinase inhibitor for treating or preventing brain cancer
JP2010507384A (ja) * 2006-10-27 2010-03-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤のプロファイリング方法
CA2664148A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Vegfr3 inhibitors
JP2010507628A (ja) * 2006-10-27 2010-03-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 骨ガンの処置又は予防のためのｍｔｋｉ１の使用
EP2123627B1 (en) * 2007-01-19 2013-11-20 Ube Industries, Ltd. Process for producing aromatic amine having aralkyloxy or heteroaralkyloxy group
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
MY169791A (en) 2008-10-22 2019-05-15 Array Biopharma Inc Substituted pyrazolo [1,5-a] pyrimidine compounds as trk kinase inhibitors
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI406853B (zh) * 2010-04-07 2013-09-01 Dev Center Biotechnology Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
ME03376B (me) 2010-05-20 2020-01-20 Array Biopharma Inc Makrociklička jedinjenja kао inhibiтori trk kinaze
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
DK2822953T5 (en) * 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
RU2733405C2 (ru) * 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
CN113354649B (zh) 2014-11-16 2024-12-10 阵列生物制药公司 一种新的晶型
JP6740354B2 (ja) 2015-10-05 2020-08-12 ザ トラスティーズ オブ コロンビア ユニバーシティー イン ザ シティー オブ ニューヨーク オートファジーの流れ及びホスホリパーゼｄ及びタウを含むタンパク質凝集体のクリアランスの活性化剤ならびにタンパク質症の治療方法
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
EP3423113B1 (en) 2016-02-29 2020-09-02 Oncodesign S.A. Radiolabeled macrocyclic egfr inhibitor
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
FI3439662T3 (fi) 2016-04-04 2024-09-04 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin nesteformulaatioita
EP3458456B1 (en) 2016-05-18 2020-11-25 Loxo Oncology Inc. Preparation of (s)-n-(5-((r)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
IL275121B2 (en) 2017-12-07 2025-11-01 Amplyx Pharmaceuticals Inc Heterocycle substituted pyridine derivative antifungal agents
KR20210023984A (ko) 2018-06-25 2021-03-04 앰플릭스 파마슈티컬스, 인크. 헤테로환형 고리 및 아미노기로 치환된 피리딘 유도체
US20230126352A1 (en) * 2020-01-31 2023-04-27 Oncodesign Sa Macrocyclic rip2-kinase inhibitors
US20230159556A1 (en) * 2020-04-20 2023-05-25 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
WO2023114809A1 (en) 2021-12-16 2023-06-22 Kinnate Biopharma Inc. Inhibitors of met kinase
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途
WO2026008023A1 (zh) * 2024-07-04 2026-01-08 正大天晴药业集团股份有限公司 哒嗪胺类化合物及其医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (pt) * 1956-06-11
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) * 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4160836A (en) 1976-05-17 1979-07-10 Janssen Pharmaceutica N.V. Antiemetic 1-(benzothiazolylalkyl)piperidine derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EA001595B1 (ru) 1996-04-12 2001-06-25 Варнер-Ламберт Компани Необратимые ингибиторы тирозинкиназ
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ATE232205T1 (de) 1998-10-01 2003-02-15 Astrazeneca Ab Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
FR2809400B1 (fr) * 2000-05-25 2004-04-09 Inst Francais Du Petrole Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral
JO2785B1 (en) 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف

Also Published As

Publication number Publication date
AU2004243487A1 (en) 2004-12-09
TW201245111A (en) 2012-11-16
MY148633A (en) 2013-05-15
IL172154A0 (en) 2006-04-10
ES2381976T3 (es) 2012-06-04
TW201245160A (en) 2012-11-16
AR045687A1 (es) 2005-11-09
ATE544454T1 (de) 2012-02-15
AU2004243487B2 (en) 2009-12-03
JO2785B1 (en) 2014-03-15
US9273013B2 (en) 2016-03-01
IS8077A (is) 2005-10-14
JP2007504276A (ja) 2007-03-01
EP1633365A1 (en) 2006-03-15
HK1176350A1 (zh) 2013-07-26
PA8603801A1 (es) 2004-12-16
TWI468397B (zh) 2015-01-11
KR101143878B1 (ko) 2012-05-24
IL233045A0 (en) 2014-07-31
SI1633365T1 (sl) 2012-06-29
JP4887151B2 (ja) 2012-02-29
MXPA05012762A (es) 2006-02-13
US7648975B2 (en) 2010-01-19
EA200501866A1 (ru) 2006-06-30
US20130178624A1 (en) 2013-07-11
CN102718775A (zh) 2012-10-10
CO5640038A2 (es) 2006-05-31
EP1633365B1 (en) 2012-02-08
TWI379835B (en) 2012-12-21
NZ544154A (en) 2009-01-31
IL233046A0 (en) 2014-07-31
HRP20120351T1 (hr) 2012-05-31
IS3030B (is) 2021-06-15
PT1633365E (pt) 2012-05-07
US20100105668A1 (en) 2010-04-29
IL233045B (en) 2018-07-31
CA2525214C (en) 2012-11-27
US20160207938A1 (en) 2016-07-21
NO334209B1 (no) 2014-01-13
NO20056196L (no) 2005-12-28
US8394786B2 (en) 2013-03-12
PL1633365T3 (pl) 2012-07-31
EP2305687A1 (en) 2011-04-06
US20060247237A1 (en) 2006-11-02
CY1113002T1 (el) 2016-04-13
EA009064B1 (ru) 2007-10-26
AR092137A2 (es) 2015-03-25
CA2525214A1 (en) 2004-12-09
KR20060014415A (ko) 2006-02-15
TW200510431A (en) 2005-03-16
BRPI0410714B1 (pt) 2019-09-24
CN102718775B (zh) 2016-02-17
DK1633365T3 (da) 2012-05-14
BRPI0410714B8 (pt) 2021-05-25
WO2004105765A1 (en) 2004-12-09
TWI468372B (zh) 2015-01-11
CL2004001267A1 (es) 2005-04-22
UA84010C2 (en) 2008-09-10

Similar Documents

Publication Publication Date Title
BRPI0410714A (pt) derivados de quinazolina
BRPI1009637A2 (pt) composto, composição e uso de um composto
BRPI0414480A (pt) derivados de 2,4-di(hetero)-arilamino-pirimidina como inibidores de zap-70 e/ou syk
NO20072689L (no) Tetrasykliske indolderivater som antivirale midler
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
BR0213790A (pt) Derivados de aminobenzamida como inibidores de glicogênio sintase cinase 3beta
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
BRPI0720742B8 (pt) derivados de heteroaril pirrolidinil e piperidinil cetona, seus usos e composição farmacêutica compreendo os mesmos
BR0317572A (pt) Benzoxazinas e seus derivados como inibidores de pi3ks
PH12012500487A1 (en) Herbicidal pyrimidone derivatives
MY153763A (en) Quinazolinedione derivatives, preparation thereof and therapeutic uses thereof
WO2008099874A1 (ja) ピラジン誘導体を含有する医薬組成物およびピラジン誘導体を組み合わせて使用する方法
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
WO2007126900A3 (en) Antifungal agents
WO2008049855A3 (en) 7-azaindole derivatives as c-met kinase inhibitors
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
BRPI0416853A (pt) pirazolila e imidazolila pirimidinas
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
TW200509948A (en) Prevention of urogenital infections
WO2008003854A3 (fr) Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique
BR0315302A (pt) Benzoxazinonas substituìdas e seus usos
MX2007013624A (es) Inhibidores de proteina cinasa.
BRPI0408204A (pt) derivados de quinolinona/benzoxazinona e usos dos mesmos
BR112012009311A2 (pt) composto, composição farmacêutica, e, uso do composto
NO20092655L (no) 2-kinolinon- og 2-kinoksalinonderivater og deres anvendelse som antibakterielle midler

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/05/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2828 DE 18-03-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.